ZILICO has received EC certification from its Notified Body for the ZedScan cervical cancer diagnostics device, which is said to offer faster and more accurate detection of cervical neoplasia in real-time, enabling clinicians to improve patient management.
The ZedScan system is used alongside colposcopy on women identified with an abnormal smear result. It can offer clinical benefits by identifying the optimum biopsy site, reducing the number of cervical biopsies required while also facilitating a wider use of ‘select & treat’.
The system, which is both safe and painless, consists of a portable hand-held device and docking station, software application and a single-use EIS sensor. Five clinical trials in the UK and EU have supported the clinical efficacy of ZedScan, including a pivotal European trial of 429 women in 2011 across three hospitals in the UK and Ireland.
